In the first half, Ildong Pharmaceutical 4.35%ㆍDaewon Pharmaceutical 3.44%p↑… Green CrossㆍCelltrionㆍDong-A ST above 20%
[Newsmp] In June, foreigners’ stake in Ildong Pharmaceutical ramped up more than 5%p.
According to the Korea Exchange, as of the end of June, foreign ownership of Ildong Pharmaceutical stood at 8.15%, up 5.61%p from the end of the previous month.
Foreign ownership in Ildong Holdings and Bukwang Pharmaceutical gained 2.13%p and 2.08%p.
Moreover, foreigners’ stake in Daewon Pharmaceutical, Yungjin Pharm., and Korea United Pharm., rose by more than 1%, and their ownership, accordingly, 6 out of 46 pharmaceutical index stocks expanded by more than 1%.
During this period, 23 out of 46 stocks saw their foreigners’ stake fall and 23 companies increase, resulting in a balance, but six stocks expanded by more than 1%p, while none declined by more than 1%.
Compared to the end of last year, Ildong Pharmaceutical’s foreign ownership increased by 4.35%p, the largest increase, and Daewon Pharmaceutical’s also jumped by 3.44%p.
In addition, Ildong Holdings rose 2.79%p, Dongwha Pharm 2.62%p, and JW Pharmaceutical 2.27%p, while Yuyu Pharmaceutical, Pharmicell, Gene One Life Science, and Yuhan Corporation gained more than 1 %p.
On the other hand, during the same period, Shin Poong Pharmaceutical’s foreign ownership plunged 5.29%, the largest decline. Samjin Pharmaceutical contracted 1.68%p, SK Bioscience 1.65%p, Chong Kun Dang Holdings 1.44%p, Samsung Pharmaceutical 1.38%p, Hyundai Pharmaceutical 1.27%p, and Kwang Dong Pharmaceutical 1.26%p.
In the first half of the year, foreign ownership of 24 stocks decreased and 22 stocks increased.
Stocks with foreigners’ stake above 10% remained the same in all 11 stocks at the end of last year, at the end of May, and at the end of June.
However, the number of stocks exceeding 20% increased to three at the end of June after decreasing from four at the end of last year to two at the end of May.
In the meantime, Green Cross’ foreign ownership was the highest at 22.74% as of the end of June, Celltrion, which had fallen below the 20% mark at the end of May, returned to 20.45%, and Dong-A ST maintained the 20% level at 20.01%.
Kwang Dong Pharmaceutical was next with 18.82%, followed by Yuhan Corporation with 18.19%, Daewong Pharmaceutical with 17.11%, exceeding 15%, Whanin Pharmaceutical with 14.29%, Gene One Life Science with 13.67%, Hanmi Pharmaceutical with 13.38%, Samsung Biologics with 10.66%, and Il-Yang Pharmaceutical with 10.36%.
